## Susan L Mcelroy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6644273/publications.pdf

Version: 2024-02-01

194 papers 16,398 citations

59 h-index 121 g-index

203 all docs 203 docs citations

times ranked

203

12685 citing authors

#	Article	IF	Citations
1	Comparison of Demographic and Clinical Features of Bipolar Disorder in Persons of African and European Ancestry. Journal of Racial and Ethnic Health Disparities, 2023, 10, 367-372.	3.2	1
2	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. Australian and New Zealand Journal of Psychiatry, 2023, 57, 93-103.	2.3	3
3	The potential role of stimulants in treating eating disorders. International Journal of Eating Disorders, 2022, 55, 318-331.	4.0	13
4	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. Journal of Affective Disorders, 2022, 300, 41-49.	4.1	6
5	Differences in perceived life stress in bipolar I and II disorder: Implications for future epigenetic quantification. Personalized Medicine in Psychiatry, 2022, 33-34, 100093.	0.1	O
6	Quantification of diet quality utilizing the rapid eating assessment for participants-shortened version in bipolar disorder: Implications for prospective depression and cardiometabolic studies. Journal of Affective Disorders, 2022, 310, 150-155.	4.1	5
7	The genetics of bipolar disorder with obesity and type 2 diabetes. Journal of Affective Disorders, 2022, 313, 222-231.	4.1	6
8	Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial. CNS Spectrums, 2021, 26, 481-490.	1.2	21
9	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LiTMUS trials. Depression and Anxiety, 2021, 38, 114-123.	4.1	5
10	The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder. Current Medical Research and Opinion, 2021, 37, 135-144.	1.9	15
11	The use of melatonin to mitigate the adverse metabolic side effects of antipsychotics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 371-382.	1.8	1
12	A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa. International Journal of Eating Disorders, 2021, 54, 872-878.	4.0	7
13	Body mass index and blood pressure in bipolar patients: Target cardiometabolic markers for clinical practice. Journal of Affective Disorders, 2021, 282, 637-643.	4.1	7
14	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. Journal of Psychiatric Research, 2021, 140, 205-213.	3.1	5
15	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. Psychiatry Research, 2021, 305, 114194.	3.3	1
16	Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity. Journal of Affective Disorders, 2021, 295, 156-162.	4.1	3
17	Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder. Contemporary Clinical Trials, 2021, 110, 106587.	1.8	1
18	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. Journal of Affective Disorders, 2020, 266, 772-781.	4.1	13

#	Article	IF	CITATIONS
19	More assortative mating in US compared to European parents and spouses of patients with bipolar disorder: implications for psychiatric illness in the offspring. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 237-245.	3.2	4
20	An Innovative Diseaseâ€Drugâ€Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate. Clinical and Translational Science, 2020, 13, 88-97.	3.1	5
21	Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A metaâ€analysis of randomized controlled trials. Bipolar Disorders, 2020, 22, 109-120.	1.9	17
22	The impact of sample processing on inflammatory markers in serum: Lessons learned. World Journal of Biological Psychiatry, 2020, 21, 230-237.	2.6	5
23	Evening chronotype as a discrete clinical subphenotype in bipolar disorder. Journal of Affective Disorders, 2020, 266, 556-562.	4.1	31
24	Call to action regarding the vascularâ€bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders. Bipolar Disorders, 2020, 22, 440-460.	1.9	66
25	Medication for Binge Eating. , 2020, , 227-241.		1
26	Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder. primary care companion for CNS disorders, The, 2020, 22, .	0.6	1
27	Clinical phenotype and genetic risk factors for bipolar disorder with binge eating: an update. Expert Review of Neurotherapeutics, 2019, 19, 867-879.	2.8	4
28	Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opinion on Investigational Drugs, 2019, 28, 1081-1094.	4.1	22
29	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. Journal of Affective Disorders, 2019, 259, 164-172.	4.1	13
30	A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder. Quality of Life Research, 2019, 28, 3385-3394.	3.1	7
31	Association of Cytomegalovirus and <i>Toxoplasma gondii</i> Antibody Titers With Bipolar Disorder. JAMA Psychiatry, 2019, 76, 1285.	11.0	36
32	Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. International Journal of Obesity, 2019, 43, 2085-2094.	3.4	13
33	GWAS of Suicide Attempt in Psychiatric Disorders and Association With Major Depression Polygenic Risk Scores. American Journal of Psychiatry, 2019, 176, 651-660.	7.2	186
34	Update on Binge Eating Disorder. Medical Clinics of North America, 2019, 103, 669-680.	2.5	47
35	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	21.4	1,191
36	Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications. Sexual Medicine Reviews, 2019, 7, 380-392.	2.9	5

#	Article	IF	Citations
37	Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder. Psychiatry Research - Neuroimaging, 2019, 286, 53-59.	1.8	24
38	Factor analysis of the eating disorder diagnostic scale in individuals with bipolar disorder. Eating Behaviors, 2019, 33, 30-33.	2.0	4
39	Statistical methods for testing X chromosome variant associations: application to sex-specific characteristics of bipolar disorder. Biology of Sex Differences, 2019, 10, 57.	4.1	6
40	Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review. Clinical Neuropharmacology, 2019, 42, 214-216.	0.7	11
41	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	28.9	935
42	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. Journal of Affective Disorders, 2019, 246, 126-131.	4.1	11
43	Placebo response and cessation in binge eating disorder: A pooled analysis of two randomized parallelâ€group clinical trials. European Eating Disorders Review, 2019, 27, 421-428.	4.1	3
44	Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa. CNS Drugs, 2019, 33, 31-46.	5.9	33
45	Bipolar disorder with binge eating behavior: a genome-wide association study implicates PRR5-ARHGAP8. Translational Psychiatry, 2018, 8, 40.	4.8	17
46	Would glucagon-like peptide-1 receptor agonists have efficacy in binge eating disorder and bulimia nervosa? A review of the current literature. Medical Hypotheses, 2018, 111, 90-93.	1.5	16
47	Food addiction: Prevalence, psychopathological correlates and associations with quality of life in a large sample. Journal of Psychiatric Research, 2018, 96, 145-152.	3.1	115
48	The relative influence of individual risk factors for attempted suicide in patients with bipolar I versus bipolar II disorder. Journal of Affective Disorders, 2018, 225, 489-494.	4.1	37
49	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. Journal of Affective Disorders, 2018, 225, 563-568.	4.1	18
50	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disorders, 2018, 21, 350-360.	1.9	5
51	Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. Translational Psychiatry, 2018, 8, 188.	4.8	44
52	113 Dasotraline for the Treatment of Moderate to Severe Binge Eating Disorder in Adults: Results From a Randomized, Double-Blind, Placebo-Controlled Study. CNS Spectrums, 2018, 23, 72-73.	1.2	5
53	Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study. Innovations in Clinical Neuroscience, 2018, 15, 17-21.	0.1	16
54	Binge Eating Disorder. Psychiatric Clinics of North America, 2017, 40, 255-266.	1.3	45

#	Article	IF	CITATIONS
55	Bipolar mixed features – Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq1	1 0.784314 4.1	rgBT/Overloc
56	A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder. Journal of Clinical Psychopharmacology, 2017, 37, 315-322.	1.4	44
57	Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, doubleâ€blind, placeboâ€controlled trials in adults with bingeâ€eating disorder. International Journal of Eating Disorders, 2017, 50, 884-892.	4.0	24
58	Clinical correlates of acute bipolar depressive episode with psychosis. Journal of Affective Disorders, 2017, 217, 29-33.	4.1	19
59	Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study. Advances in Therapy, 2017, 34, 2307-2315.	2.9	37
60	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. Journal of Affective Disorders, 2017, 223, 146-152.	4.1	18
61	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. Journal of Psychiatric Research, 2017, 95, 208-212.	3.1	4
62	Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder. JAMA Psychiatry, 2017, 74, 903.	11.0	106
63	A genome wide association study suggests the association of muskelin with early onset bipolar disorder: Implications for a GABAergic epileptogenic neurogenesis model. Journal of Affective Disorders, 2017, 208, 120-129.	4.1	17
64	Pharmacologic Treatments for Binge-Eating Disorder. Journal of Clinical Psychiatry, 2017, 78, 14-19.	2.2	51
65	Differential SLC1A2 Promoter Methylation in Bipolar Disorder With or Without Addiction. Frontiers in Cellular Neuroscience, 2017, 11, 217.	3.7	26
66	Bipolar Disorder and Eating Disorders. , 2017, , 60-65.		0
67	Novel pharmacologic treatment in acute binge eating disorder & mp; ndash; role of lisdexamfetamine. Neuropsychiatric Disease and Treatment, 2016, 12, 833.	2.2	31
68	Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive–Compulsive and Impulsive Features in Adults with Binge Eating Disorder. European Eating Disorders Review, 2016, 24, 223-231.	4.1	57
69	Mixed Depression in Bipolar Disorder: Prevalence Rate and Clinical Correlates During Naturalistic Follow-Up in the Stanley Bipolar Network. American Journal of Psychiatry, 2016, 173, 1015-1023.	7.2	52
70	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. Journal of Affective Disorders, 2016, 205, 159-164.	4.1	7
71	Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial. Human Psychopharmacology, 2016, 31, 382-391.	1.5	20
72	Managing comorbid obesity and depression through clinical pharmacotherapies. Expert Opinion on Pharmacotherapy, 2016, 17, 1599-1610.	1.8	7

#	Article	IF	CITATIONS
73	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics, 2016, 25, 3383-3394.	2.9	182
74	Clinical features of bipolar spectrum with binge eating behaviour. Journal of Affective Disorders, 2016, 201, 95-98.	4.1	29
75	Accumulating evidence for a role of <scp>TCF</scp> 7L2 variants in bipolar disorder with elevated body mass index. Bipolar Disorders, 2016, 18, 124-135.	1.9	27
76	Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology, 2016, 41, 1251-1260.	5.4	205
77	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. Journal of Affective Disorders, 2016, 192, 212-218.	4.1	22
78	Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. Journal of Affective Disorders, 2016, 191, 216-221.	4.1	62
79	Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness). Journal of Clinical Psychiatry, 2016, 77, 90-99.	2.2	69
80	The Dual Epidemic of Tobacco Dependence and Obesity Among Those With Severe Mental Illness. Journal of Clinical Psychiatry, 2016, 77, e327-e328.	2.2	2
81	Overview of the treatment of binge eating disorder. CNS Spectrums, 2015, 20, 546-556.	1.2	63
82	National Survey and Community Advisory Board Development for a Bipolar Disorder Biobank. Bipolar Disorders, 2015, 17, 598-605.	1.9	14
83	Sex differences in the risk of rapid cycling and other indicators of adverse illness course in patients with bipolar I and II disorder. Bipolar Disorders, 2015, 17, 670-676.	1.9	37
84	Association between history of psychosis and cardiovascular disease in bipolar disorder. Bipolar Disorders, 2015, 17, 518-527.	1.9	12
85	Armodafinil in binge eating disorder. International Clinical Psychopharmacology, 2015, 30, 209-215.	1.7	24
86	Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar <scp>CHOICE</scp> ). Bipolar Disorders, 2015, 17, 212-223.	1.9	77
87	Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder. JAMA Psychiatry, 2015, 72, 235.	11.0	261
88	Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analyses. International Journal of Bipolar Disorders, 2015, 3, 30.	2.2	55
89	Psychopharmacologic Treatment of Eating Disorders: Emerging Findings. Current Psychiatry Reports, 2015, 17, 35.	4.5	53
90	Adjunctive lisdexamfetamine in bipolar depression. International Clinical Psychopharmacology, 2015, 30, 6-13.	1.7	31

#	Article	IF	CITATIONS
91	Validation of the yaleâ€brown obsessive compulsive scale modified for binge eating. International Journal of Eating Disorders, 2015, 48, 994-1004.	4.0	32
92	Placebo Cessation in Binge Eating Disorder: Effect on Anthropometric, Cardiovascular, and Metabolic Variables. European Eating Disorders Review, 2015, 23, 86-88.	4.1	6
93	The Epidemic of Depression With Obesity. Journal of Clinical Psychiatry, 2015, 76, e1340-e1342.	2.2	15
94	Successful Treatment of Binge Eating Disorder With Combination Phentermine/Topiramate Extended Release. primary care companion for CNS disorders, The, 2015, 17, .	0.6	12
95	Eating Disorders: Binge Eating. , 2014, , 1-6.		0
96	A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World Journal of Biological Psychiatry, 2014, 15, 96-112.	2.6	38
97	Placebo Response in Binge Eating Disorder: A Pooled Analysis of 10 Clinical Trials from One Research Group. European Eating Disorders Review, 2014, 22, 140-146.	4.1	27
98	Bipolar disorder with comorbid binge eating history: A genome-wide association study implicates APOB. Journal of Affective Disorders, 2014, 165, 151-158.	4.1	34
99	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. Journal of Affective Disorders, 2014, 161, 30-35.	4.1	18
100	Treating Nonsuicidal Self-Injury. Current Treatment Options in Psychiatry, 2014, 1, 325-334.	1.9	7
101	Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar) Tj ETQq1 1 0.7 114-127.	'84314 rgl 1.6	BT /Overlock 60
102	Metabolic Syndrome in Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, 46-61.	2.2	76
103	Clinical phenotype of bipolar disorder with comorbid binge eating disorder. Journal of Affective Disorders, 2013, 150, 981-986.	4.1	56
104	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
105	Heritability and linkage analysis of personality in bipolar disorder. Journal of Affective Disorders, 2013, 151, 748-755.	4.1	22
106	Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. International Journal of Bipolar Disorders, 2013, 1, 10.	2.2	28
107	Role of childhood adversity in the development of medical co-morbidities associated with bipolar disorder. Journal of Affective Disorders, 2013, 147, 288-294.	4.1	66
108	N-acetylcysteine in bulimia nervosa â€" Open-label trial. Eating Behaviors, 2013, 14, 87-89.	2.0	6

#	Article	IF	CITATIONS
109	Zonisamide in the treatment of bulimia nervosa: An openâ€label, pilot, prospective study. International Journal of Eating Disorders, 2013, 46, 747-750.	4.0	13
110	A placeboâ€controlled pilot study of the novel opioid receptor antagonist ALKSâ€33 in binge eating disorder. International Journal of Eating Disorders, 2013, 46, 239-245.	4.0	41
111	Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder. primary care companion for CNS disorders, The, 2013, 15, .	0.6	23
112	Adjunctive Methylphenidate in the Treatment of Bulimia Nervosa Co-occurring with Bipolar Disorder and Substance Dependence. Innovations in Clinical Neuroscience, 2013, 10, 30-3.	0.1	5
113	A Randomized, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain. Journal of Clinical Psychopharmacology, 2012, 32, 165-172.	1.4	28
114	Current pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opinion on Pharmacotherapy, 2012, 13, 2015-2026.	1.8	34
115	Obesity in Bipolar Disorder: An Overview. Current Psychiatry Reports, 2012, 14, 650-658.	4.5	103
116	Pharmacological management of binge eating disorder: current and emerging treatment options. Therapeutics and Clinical Risk Management, 2012, 8, 219.	2.0	61
117	Pharmacogenomics of antidepressant induced mania: A review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. Journal of Affective Disorders, 2012, 136, e21-e29.	4.1	36
118	Duloxetine in the treatment of binge eating disorder with depressive disorders: A placeboâ€controlled trial. International Journal of Eating Disorders, 2012, 45, 281-289.	4.0	65
119	Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. Journal of Affective Disorders, 2011, 128, 191-198.	4.1	136
120	Sodium oxybate in the treatment of binge eating disorder: An openâ€label, prospective study. International Journal of Eating Disorders, 2011, 44, 262-268.	4.0	27
121	Acamprosate in the treatment of binge eating disorder: A placeboâ€controlled trial. International Journal of Eating Disorders, 2011, 44, 81-90.	4.0	50
122	Broadening bipolar diagnostic criteria: why not start with hypomania?. World Psychiatry, 2011, 10, 189-191.	10.4	1
123	Bipolar Disorder with Co-Occurring Eating Disorders: Prevalence and Pharmacotherapeutic Implications. Focus (American Psychiatric Publishing), 2011, 9, 435-448.	0.8	3
124	Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. Journal of Affective Disorders, 2010, 124, 157-163.	4.1	31
125	Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder. American Journal of Clinical Nutrition, 2010, 91, 1568-1573.	4.7	251
126	Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opinion on Investigational Drugs, 2010, 19, 1527-1544.	4.1	12

#	Article	IF	Citations
127	Randomized, Double-Blind, Placebo-Controlled Study of Divalproex Extended Release Loading Monotherapy in Ambulatory Bipolar Spectrum Disorder Patients With Moderate-to-Severe Hypomania or Mild Mania. Journal of Clinical Psychiatry, 2010, 71, 557-565.	2.2	27
128	A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II). Journal of Clinical Psychiatry, 2010, 71, 163-174.	2.2	250
129	A Double-Blind, Placebo-Controlled Study of Quetiapine and Lithium Monotherapy in Adults in the Acute Phase of Bipolar Depression (EMBOLDEN I). Journal of Clinical Psychiatry, 2010, 71, 150-162.	2.2	305
130	Role of Antiepileptic Drugs in the Management of Eating Disorders. CNS Drugs, 2009, 23, 139-156.	5.9	66
131	Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. International Clinical Psychopharmacology, 2009, 24, 150-158.	1.7	57
132	Obesity in Patients With Severe Mental Illness. Journal of Clinical Psychiatry, 2009, 70, 12-21.	2.2	71
133	Highâ€dose escitalopram in the treatment of bingeâ€eating disorder with obesity: a placeboâ€controlled monotherapy trial. Human Psychopharmacology, 2008, 23, 1-11.	1.5	62
134	Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. Journal of Affective Disorders, 2008, 107, 127-133.	4.1	18
135	Antiepileptic Drugs in Obesity, Psychotropic-Associated Weight Gain, and Eating Disorders. Medical Psychiatry, 2008, , 283-310.	0.2	4
136	Understanding the Complexity of Bipolar Mixed Episodes. Journal of Clinical Psychiatry, 2008, 69, e06.	2.2	17
137	Co-Occurrence of Binge Eating Disorder With Psychiatric and Medical Disorders. Journal of Clinical Psychiatry, 2008, 69, 266-273.	2.2	198
138	Olanzapine in the Treatment of Pathological Gambling. Journal of Clinical Psychiatry, 2008, 69, 433-440.	2.2	140
139	A Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression. American Journal of Psychiatry, 2007, 164, 1242-1249.	7.2	224
140	Topiramate for the Treatment of Binge Eating Disorder Associated With Obesity: A Placebo-Controlled Study. Biological Psychiatry, 2007, 61, 1039-1048.	1.3	244
141	A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disorders, 2007, 9, 426-434.	1.9	65
142	Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. Journal of Affective Disorders, 2007, 101, 275-281.	4.1	50
143	Atomoxetine in the Treatment of Binge-Eating Disorder. Journal of Clinical Psychiatry, 2007, 68, 390-398.	2.2	124
144	Substance Use Disorders and Overweight/Obesity in Bipolar I Disorder. Journal of Clinical Psychiatry, 2007, 68, 1352-1357.	2.2	65

#	Article	IF	Citations
145	Bipolarity in Women: Therapeutic Issues. , 2006, , 235-277.		3
146	A Comparison of "Second Generation Antipsychotics―in the Treatment for Bipolar Disorder: Focus on Clozapine, Quetiapine, Ziprasidone and Aripiprazole. , 2006, , 125-134.		1
147	Binge-Eating Disorder as a Distinct Familial Phenotype in Obese Individuals. Archives of General Psychiatry, 2006, 63, 313.	12.3	147
148	Antidepressants and suicidal behavior in bipolar disorder. Bipolar Disorders, 2006, 8, 596-617.	1.9	54
149	Comorbidity of eating disorders with bipolar disorder and treatment implications. Bipolar Disorders, 2006, 8, 686-695.	1.9	87
150	Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity. Human Psychopharmacology, 2006, 21, 425-431.	1.5	16
151	Risk of Switch in Mood Polarity to Hypomania or Mania in Patients With Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers. American Journal of Psychiatry, 2006, 163, 232-239.	7.2	379
152	Medical Management of Obesity Associated with Mood Disorders. Medical Psychiatry, 2006, , 369-416.	0.2	1
153	Zonisamide in the Treatment of Binge Eating Disorder With Obesity. Journal of Clinical Psychiatry, 2006, 67, 1897-1906.	2.2	127
154	Response of Recurrent Binge Eating and Weight Gain to Topiramate in Patients with Binge Eating Disorder after Bariatric Surgery. Obesity Surgery, 2005, 15, 273-277.	2.1	29
155	Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations?. Journal of Affective Disorders, 2005, 86, 107-127.	4.1	154
156	Comparison of Rapid-Cycling and Non-Rapid-Cycling Bipolar Disorder Based on Prospective Mood Ratings in 539 Outpatients. American Journal of Psychiatry, 2005, 162, 1273-1280.	7.2	184
157	Mixed Hypomania in 908 Patients With Bipolar Disorder Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Network. Archives of General Psychiatry, 2005, 62, 1089.	12.3	175
158	Open-Label Adjunctive Zonisamide in the Treatment of Bipolar Disorders. Journal of Clinical Psychiatry, 2005, 66, 617-624.	2.2	65
159	Bipolar Disorders: Special Diagnostic and Treatment Considerations in Women. CNS Spectrums, 2004, 9, 5-18.	1.2	21
160	Pharmacological Approaches in the Treatment of Binge Eating Disorder. Current Drug Targets, 2004, 5, 301-307.	2.1	56
161	Zonisamide in the Treatment of Binge-Eating Disorder. Journal of Clinical Psychiatry, 2004, 65, 50-56.	2.2	64
162	A 52-Week, Open-Label Continuation Study of Lamotrigine in the Treatment of Bipolar Depression. Journal of Clinical Psychiatry, 2004, 65, 204-210.	2.2	53

#	Article	IF	CITATIONS
163	Are Mood Disorders and Obesity Related? A Review for the Mental Health Professional. Journal of Clinical Psychiatry, 2004, 65, 634-651.	2.2	528
164	Topiramate in the Long-Term Treatment of Binge-Eating Disorder Associated with Obesity. Journal of Clinical Psychiatry, 2004, 65, 1463-1469.	2.2	123
165	Diagnosing and treating comorbid (complicated) bipolar disorder. Journal of Clinical Psychiatry, 2004, 65 Suppl 15, 35-44.	2.2	11
166	Pharmacologic treatment of binge eating disorder. International Journal of Eating Disorders, 2003, 34, S74-S88.	4.0	134
167	Topiramate in the Treatment of Binge Eating Disorder Associated With Obesity: A Randomized, Placebo-Controlled Trial. American Journal of Psychiatry, 2003, 160, 255-261.	7.2	481
168	Citalopram in the Treatment of Binge-Eating Disorder. Journal of Clinical Psychiatry, 2003, 64, 807-813.	2.2	108
169	Bipolar Disorder, Obesity, and Pharmacotherapy-Associated Weight Gain. Journal of Clinical Psychiatry, 2003, 64, 1426-1435.	2.2	182
170	Orlistat Misuse in Bulimia Nervosa. American Journal of Psychiatry, 2002, 159, 492-a-493.	7.2	18
171	A double-blind, placebo-controlled trial of eicosapentanoic acid in rapid cycling bipolar disorder. Bipolar Disorders, 2002, 4, 26-27.	1.9	10
172	Correlates of Overweight and Obesity in 644 Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2002, 63, 207-213.	2.2	281
173	Venlafaxine Treatment of Binge-Eating Disorder Associated With Obesity. Journal of Clinical Psychiatry, 2002, 63, 802-806.	2.2	69
174	A Placebo-Controlled, Randomized Trial of Fluoxetine in the Treatment of Binge-Eating Disorder. Journal of Clinical Psychiatry, 2002, 63, 1028-1033.	2.2	138
175	Psychogenic Excoriation. CNS Drugs, 2001, 15, 351-359.	5.9	237
176	Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disorders, 2001, 3, 53-57.	1.9	170
177	A pilot study of rapid lithium administration in the treatment of acute mania. Bipolar Disorders, 2001, 3, 68-72.	1.9	24
178	Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders, 2001, 3, 259-265.	1.9	97
179	The Stanley Foundation Bipolar Treatment Outcome Network. Journal of Affective Disorders, 2001, 67, 33-44.	4.1	162
180	The Stanley Foundation Bipolar Treatment Outcome Network. Journal of Affective Disorders, 2001, 67, 45-59.	4.1	436

#	Article	IF	Citations
181	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s177-s183.	2.8	39
182	Ziprasidone: a new atypical antipsychotic. Expert Opinion on Pharmacotherapy, 2001, 2, 1033-1042.	1.8	37
183	Axis I Psychiatric Comorbidity and Its Relationship to Historical Illness Variables in 288 Patients With Bipolar Disorder. American Journal of Psychiatry, 2001, 158, 420-426.	7.2	611
184	Pharmacologic loading in the treatment of acute mania. Bipolar Disorders, 2000, 2, 42-46.	1.9	21
185	Development and Validation of a Screening Instrument for Bipolar Spectrum Disorder: The Mood Disorder Questionnaire. American Journal of Psychiatry, 2000, 157, 1873-1875.	7.2	1,202
186	Treatment of Binge-Eating Disorder With Topiramate. Journal of Clinical Psychiatry, 2000, 61, 368-372.	2.2	152
187	Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disorders, 1999, 1, 61-65.	1.9	57
188	Fluvoxamine in the Treatment of Binge-Eating Disorder: A Multicenter Placebo-Controlled, Double-Blind Trial. American Journal of Psychiatry, 1998, 155, 1756-1762.	7.2	193
189	Sex Offenders. Science, 1998, 279, 10d-15.	12.6	1
190	Psychotic Depression. CNS Drugs, 1997, 8, 457-473.	5.9	8
191	Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depression and Anxiety, 1997, 6, 170-173.	4.1	79
192	Relationships Among Negative, Positive, and Depressive Symptoms in Schizophrenia and Psychotic Depression. British Journal of Psychiatry, 1996, 168, 68-71.	2.8	241
193	Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome. American Journal of Medical Genetics Part A, 1995, 60, 228-230.	2.4	31
194	Clinical and theoretical implications of a possible link between obsessiveâ€compulsive and impulse control disorders. Depression, 1993, 1, 121-132.	0.6	38